CN108815516B - A method of PEDV inactivated vaccine is produced using serum free medium - Google Patents
A method of PEDV inactivated vaccine is produced using serum free medium Download PDFInfo
- Publication number
- CN108815516B CN108815516B CN201810691800.0A CN201810691800A CN108815516B CN 108815516 B CN108815516 B CN 108815516B CN 201810691800 A CN201810691800 A CN 201810691800A CN 108815516 B CN108815516 B CN 108815516B
- Authority
- CN
- China
- Prior art keywords
- content
- pedv
- serum
- taurine
- free medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 title claims abstract description 71
- 239000012679 serum free medium Substances 0.000 title claims abstract description 33
- 229940031551 inactivated vaccine Drugs 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 82
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 53
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 48
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 48
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 41
- 229960003080 taurine Drugs 0.000 claims abstract description 41
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 40
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 40
- 239000011781 sodium selenite Substances 0.000 claims abstract description 40
- 102000004877 Insulin Human genes 0.000 claims abstract description 24
- 108090001061 Insulin Proteins 0.000 claims abstract description 24
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 24
- 229940125396 insulin Drugs 0.000 claims abstract description 24
- 239000007640 basal medium Substances 0.000 claims abstract description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 21
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims description 41
- 210000003501 vero cell Anatomy 0.000 claims description 34
- 108010024636 Glutathione Proteins 0.000 claims description 26
- 229960003180 glutathione Drugs 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 12
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims 4
- 108090000901 Transferrin Proteins 0.000 claims 4
- 102000004142 Trypsin Human genes 0.000 claims 4
- 108090000631 Trypsin Proteins 0.000 claims 4
- 239000012581 transferrin Substances 0.000 claims 4
- 229960001322 trypsin Drugs 0.000 claims 4
- 239000012588 trypsin Substances 0.000 claims 4
- 229940082569 selenite Drugs 0.000 claims 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 29
- 238000004519 manufacturing process Methods 0.000 abstract description 24
- 102000002070 Transferrins Human genes 0.000 abstract description 20
- 108010015865 Transferrins Proteins 0.000 abstract description 20
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000001963 growth medium Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 32
- 238000012360 testing method Methods 0.000 description 28
- 229960005486 vaccine Drugs 0.000 description 25
- 241000282898 Sus scrofa Species 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000006285 cell suspension Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000012930 cell culture fluid Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000005374 membrane filtration Methods 0.000 description 7
- 231100000614 poison Toxicity 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- -1 trypsase Chemical compound 0.000 description 6
- 229940031567 attenuated vaccine Drugs 0.000 description 5
- 238000011031 large-scale manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001411320 Eriogonum inflatum Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015856 Extrasystoles Diseases 0.000 description 2
- 241001071864 Lethrinus laticaudis Species 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C12N2501/855—Corticotropin [ACTH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a kind of methods using serum free medium production PEDV inactivated vaccine; the serum free medium is by basal medium; bovine serum albumin(BSA); cortisol, insulin, transferrins; glutathione; trypsase, taurine and sodium selenite composition, wherein the weight ratio of taurine and sodium selenite is 2-3:1.This method does not add animal blood serum, significantly reduces production cost, improves the economic benefit of production, and also avoids serum and use brought problems.
Description
Technical field:
The present invention relates to field of biotechnology, and in particular to a kind of to produce PEDV inactivated vaccine using serum free medium
Method.
Background technique:
Pig epidemic diarrhea (PED) is acute and highly infectious intestines as caused by Porcine epidemic diarrhea virus (PEDV)
Road viral disease, symptom include diarrhea, vomiting, anorexia, and dehydration and pig weight mitigate.Although the pig of different age group is all
By different degrees of infection and symptom may occur, but the state of an illness especially severe of piglet, wherein the death rate is up to 100%,
The intestinal mucosal surface that PEDV mainly passes through piggy enters host, mainly results in enterocyte damage.Although different age group
Pig all by different degrees of infection and symptom may occur, but the state of an illness especially severe of piglet, and wherein the death rate is up to
The intestinal mucosal surface that 100%, PEDV mainly pass through piggy enters host, mainly results in enterocyte damage.For PEDV's
Great outburst, we can usually control PEDV using vaccination, and carried out with kill extensively or subtracted in China
The PEDV vaccine of poison carries out vaccine inoculation, controls the large-scale outbreak of PEDV to a certain extent.But as Chinese PEDV goes out
Living or attenuation bigeminy vaccine to be widely used, PED persistently spreads in October, 2010 in China, makes a variation at that time
Strain, PEDV infection sharply increase, and seriously endanger pig breeding industry.Although the country for epidemic diarrhea vaccine (including bigeminy inactivation
Seedling and bigeminal live vaccine) extensive promotion and application have been obtained, and reduce pig epidemic in a certain range and degree
The disease incidence rushed down, but the disease still fails to be fully controlled, especially in October, 2010 so far, which is in duration, quick-fried
Hair property growth trend.
In general, PEDV is usedveroCell is cultivated and is proliferated, and then inactivates and PEDV inactivated vaccine is prepared.Mesh
Before, it is based onveroThe production process of cell culture PEDV vaccine mostly uses two stages operating procedure, it may be assumed that there is being serum in early period
Make cell Proliferation to required density in culture medium；Later period by washing removal serum composition and metabolic waste, is changed to low serum
Or serum free medium is to support virus to infect and replicate in cell.However, in existing production of vaccine, early periodveroCell
Culture solution cooperates calf or horse serum to be cultivated and produced with commercialized culture medium.The complexity of serum component and not really
Difference between qualitative and batch increases the difficulty of the cell products Production and quality control such as vaccine, while serum easily causes carefully
The pollution of bacterium, fungi, virus and mycoplasma, increases the safety risks of production of vaccine.And serum price itself also compares
Valuableness, these make application of the serum in the production and research of PEDV vaccine, and there are many unfavorable.Have been proven in practice that no blood
Clear culture medium can not only be largely avoided or improve drawbacks described above brought by serum-containing media, can also obtain compared with
Good culture effect.And since it is explicitly at being grouped as, the different batches or unknown component that can avoid serum train cell
Feeding and experimental study influence, to improve the repeatability of result.Therefore, used based on serum in PEDV production of vaccine
Existing problems and production cost are high, and therefore, the dosage for reducing serum to the greatest extent is always to study in production of vaccine
Project, the development and application of low serum and serum free medium is imperative.
Summary of the invention:
In order to solve the above technical problems, and in the prior art problems and high production cost present in serum use
High, the present invention is intended to provide a kind of method using serum free medium production PEDV inactivated vaccine, which can not add
Object serum, significantly reduces production cost, improves the economic benefit of production, and also avoids brought by serum use
Problems.
In order to solve the above technical problems, the present invention uses following technological means:
A method of PEDV inactivated vaccine being produced using serum free medium, described method includes following steps:
Step (1), the recovery of Vero cell；
Step (2), the passage amplification of Vero cell；
Step (3) is inoculated with PEDV virus stain on Vero cell；
Step (4), harvests infection cell culture supernatant, and virus liquid carries out clarification filtration；
Step (5), inactivation, that is, be prepared PEDV inactivated vaccine；
Wherein breeding viral in the passage amplification and step (3) in step (2) is all made of serum-free of the invention
Culture medium.
The serum free medium is by basal medium, bovine serum albumin(BSA), cortisol, insulin, transferrins, paddy Guang
Sweet peptide, trypsase, taurine and sodium selenite composition, wherein the weight ratio of taurine and sodium selenite is 2-3:
1。
In the serum free medium:
The basal medium IMDM(Giboc) RPMI-1640 or the two mixture；
The content of the bovine serum albumin(BSA) is 8-15mg/mL；
The content of the cortisol is 15-25 μ g/mL；
The content of the insulin is 10-20 μ g/mL；
The content of the transferrins is 10-15 μ g/mL；
The content of the glutathione is 2-3mM；
The content of the trypsase is 3-5 μ g/mL；
The content of the taurine is 20-30 μ g/mL；
The content of the sodium selenite is 10-12 μ g/mL.
Preferably, in the serum free medium:
The basal medium IMDM(Giboc) RPMI-1640 or the two mixture；
The content of the bovine serum albumin(BSA) is 10mg/mL；
The content of the cortisol is 20 μ g/mL；
The content of the insulin is 20 μ g/mL；
The content of the transferrins is 15 μ g/mL；
The content of the glutathione is 3mM；
The content of the trypsase is 4 μ g/mL；
The content of the taurine is 20 μ g/mL；
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium is: step 1 weighs basal medium dry powder, ox blood by weight
Pure albumen, cortisol, insulin, transferrins, glutathione, trypsase, taurine and sodium selenite；Step 2, will
After the weighed above material mixing, add ultrapure water to 1000mL, stirring and dissolving adjusts pH value to 7.0-7.2, then uses 0.22
μm membrane filtration degerming, 4 DEG C of preservations.
The invention further relates to the method using serum free medium culture PEDV virus of the present invention, the method packets
Include following steps:
Step (1), the recovery of Vero cell；
Step (2), the passage amplification of Vero cell；
Step (3) is inoculated with PEDV virus stain on Vero cell；
Step (4), harvests infection cell culture supernatant, and virus liquid carries out clarification filtration to get sick to the PEDV
Venom；
Wherein breeding viral in the passage amplification and step (3) in step (2) is all made of serum-free of the invention
Culture medium.
Based on above technical scheme, the invention has the advantages that and the utility model has the advantages that
The embodiment of the present invention 1 and the culture medium of embodiment 2 have preferable cultivation effect, phase to the proliferation of PEDV
Adding DMEM culture medium than existing common calf serum, can more promote the proliferation of PEDV, the virus titer of proliferation is significantly raised,
Show that culture medium of the invention can substitute traditional serum-containing media for the proliferation of PEDV and the preparation of vaccine, to keep away
Immune problem caused by the use of serum in vaccine production process is exempted from；Its compared with the control experiment group that is arranged of the present invention,
Further demonstrate glutathione addition and taurine and sodium selenite ratio for PEDV cell Proliferation importance,
Glutathione is not added in comparative experimental example 1, and there is also differences for the ratio of taurine and sodium selenite, are higher than the present invention, then
Its virus multiplication effect difference more of the present invention；The ratio of taurine and sodium selenite is 1:1 in comparative experimental example 2, i.e. taurine makes
With deficiency, then cause virus multiplication too late expected, although it is proliferated in the 0-12h stage comparatively fast, in the virus multiplication later period
Titre rises slower；Glutathione is not added in comparative experimental example 3, then virus multiplication is too late expected, and early stage is proliferated relatively
Slowly, later period proliferation also shows slightly insufficient.The above test results show that in culture medium of the invention, the addition of glutathione and ox
The ratio of sulfonic acid and sodium selenite has great importance for PEDV cell Proliferation, and the two cooperates in virus multiplication culture
Synergy achieves unexpected culture effect.
Detailed description of the invention:
The case where Fig. 1: PEDV Virus culture.A, control group, normal vero cell；B connects poison after 24 hours, and compares
The normal cell of group is compared, and more apparent CPE occurs；C connect poison after 48 hours, and cell rounding has part cells float de-
It falls, the pathological changes such as seine shape occurs.
Fig. 2: IFA testing result: A is normal vero cell controls；B is carried out using 1 culture medium of the embodiment of the present invention
IFA testing result after culture；C is the IFA testing result after being cultivated using 10% FBS DMEM cell culture fluid, and D is
The IFA testing result cultivated using the culture medium that following check experiment example is shown.
Specific embodiment:
A kind of embodiment 1: serum free medium of suitable large-scale production PEDV vaccine, which is characterized in that the no blood
Clear culture medium is by basal medium, bovine serum albumin(BSA), cortisol, insulin, transferrins, glutathione, trypsase, ox
Sulfonic acid and sodium selenite composition, wherein the weight ratio of taurine and sodium selenite is 2:1.
The basal medium IMDM(Giboc)；
The content of the bovine serum albumin(BSA) is 10mg/mL.
The content of the cortisol is 20 μ g/mL.
The content of the insulin is 20 μ g/mL.
The content of the transferrins is 15 μ g/mL.
The content of the glutathione is 3mM.
The content of the trypsase is 4 μ g/mL.
The content of the taurine is 20 μ g/mL.
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium of suitable large-scale production PEDV vaccine of the present invention is: step 1,
Basal medium dry powder, bovine serum albumin(BSA), cortisol, insulin, transferrins, glutathione, pancreas egg are weighed by weight
White enzyme, taurine and sodium selenite；Step 2 adds ultrapure water to 1000mL, stirs molten after the weighed above material mixing
Solution adjusts pH value to 7.0-7.2, then uses 0.22 μm of membrane filtration degerming, 4 DEG C of preservations.
A kind of embodiment 2: serum free medium of suitable large-scale production PEDV vaccine, which is characterized in that the no blood
Clear culture medium is by basal medium, bovine serum albumin(BSA), cortisol, insulin, transferrins, glutathione, trypsase, ox
Sulfonic acid and sodium selenite composition, wherein the weight ratio of taurine and sodium selenite is 3:1.
The basal medium IMDM(Giboc)；
The content of the bovine serum albumin(BSA) is 10mg/mL.
The content of the cortisol is 20 μ g/mL.
The content of the insulin is 20 μ g/mL.
The content of the transferrins is 15 μ g/mL.
The content of the glutathione is 3mM.
The content of the trypsase is 4 μ g/mL.
The content of the taurine is 30 μ g/mL.
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium of suitable large-scale production PEDV vaccine of the present invention is: step 1,
Basal medium dry powder, bovine serum albumin(BSA), cortisol, insulin, transferrins, glutathione, pancreas egg are weighed by weight
White enzyme, taurine and sodium selenite；Step 2 adds ultrapure water to 1000mL, stirs molten after the weighed above material mixing
Solution adjusts pH value to 7.0-7.2, then uses 0.22 μm of membrane filtration degerming, 4 DEG C of preservations.
The small-scale proliferation test of embodiment 3:PEDV
Test strain:, being obtained from Xibei Univ. of Agricultural & Forest Science & Technology by SX-YL plants of PEDV, which advises from Yangling Shaanxi
Modelling farm.
Test cell: Vero cell strain, the present of Xibei Univ. of Agricultural & Forest Science & Technology animal medicine institute veterinary vaccination laboratory.
Test method:
(1) recovery of Vero cell strain:
(1) the Vero cell being removed from liquid nitrogen quickly is put into 37 DEG C of water-baths, gently shaking makes its quick-thawing；
(2) 300 rpm are centrifuged 10 min；
(3) supernatant is abandoned, the cell culture fluid (containing 5% FBS DMEM) of 37 DEG C of pre-temperatures is added, gently dispels Vero cell；
(4) cell suspension after mixing is added to sterile T25 bottles containing 5m L5% FBS DMEM cell culture fluid
In, it is put in the suitable cell incubator of condition and cultivates；
(5) after passage twice, vero cell suspension is added in 24 orifice plates, culture to its cell in incubator is placed in and grows up to
Single layer, after being rinsed 2 times using the culture medium of the embodiment of the present invention 1, the culture medium for pouring into the embodiment of the present invention 1 is cultivated.
(2) viral inoculation, culture and IFA detection:
PEDV SX-YL strain virus liquid is diluted using the culture medium of the embodiment of the present invention 1, by Vero cell culture
In 24 well culture plates, after cells grow up to the individual layer is inoculated with PEDV, while setting the normal cell controls for not connecing poison, occurs to cell
20 min are fixed with ethyl alcohol (- 20 DEG C of pre-coolings) after Minimal change, are then washed 3 times with PBS, each 5min.PEDV N egg is added
Bai Dankang (Xibei Univ. of Agricultural & Forest Science & Technology's present), 37 DEG C of incubation 60min, PBS are washed three times, and the sheep anti mouse Ig of FITC label is added
G.Result is observed under inverted fluorescence microscope.Concrete outcome is referring to attached Fig. 1 and 2.
Wherein attached drawing 1 illustrates the case where carrying out PEDV Virus culture using 1 culture medium of the embodiment of the present invention, and it is small to connect poison 24
There is more apparent CPE compared with the normal cell of control group in Shi Hou, connects poison after 48 hours, and cell rounding has part thin
Born of the same parents' floating falls off, and the pathological changes such as seine shape occurs.
Fig. 2 illustrates IFA detection case, and wherein A is normal vero cell controls；B is trained using the embodiment of the present invention 1
Feeding base cultivated after IFA testing result；C is the IFA detection after being cultivated using 10% FBS DMEM cell culture fluid
As a result, D is the IFA testing result cultivated using the culture medium that following check experiment example is shown.The result above table of comparisons
Bright, after the culture medium of the embodiment of the present invention 1 is cultivated, fluorescence intensity and density are obviously higher than serum in the prior art
The culture medium of culture medium and check experiment example 1, illustrates: on the one hand, the culture medium of the embodiment of the present invention 1 is proliferated in PEDV
It is better than the culture medium containing serum in terms of effect, culture medium of the invention, which is fully able to replace existing serum-containing media, to be used for
The culture of PEDV virus and the preparation of proliferation and vaccine.On the other hand, 1 relative comparison test example 1 of the embodiment of the present invention,
The proportional difference of taurine and sodium selenite and the addition of glutathione are distinguished, the difference of result shows that the present invention is implemented
The addition of the ratio and glutathione of taurine and sodium selenite has important shadow for the proliferation of PEDV virus in example 1
It ringing, the addition of appropriate ratio and glutathione between the two has the function of synergy for the proliferation of PEDV virus,
It demonstrates culture medium of the invention and achieves the unexpected technology effect of those skilled in the art in terms of PEDV virus multiplication
Fruit.
Check experiment example 1 set forth below: a kind of serum free medium, which is characterized in that the serum free medium is by base
Basal culture medium, bovine serum albumin(BSA), cortisol, insulin, transferrins, trypsase, taurine and sodium selenite composition,
The weight ratio of middle taurine and sodium selenite is 4:1.
The basal medium IMDM(Giboc)；
The content of the bovine serum albumin(BSA) is 10mg/mL.
The content of the cortisol is 20 μ g/mL.
The content of the insulin is 20 μ g/mL.
The content of the transferrins is 15 μ g/mL.
The content of the trypsase is 4 μ g/mL.
The content of the taurine is 40 μ g/mL.
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium is: step 1 weighs basal medium dry powder, cow's serum by weight
Albumin, cortisol, insulin, transferrins, trypsase, taurine and sodium selenite；Step 2, by the weighed above object
After matter mixing, add ultrapure water to 1000mL, stirring and dissolving is adjusted pH value to 7.0-7.2, then removed using 0.22 μm of membrane filtration
Bacterium, 4 DEG C of preservations.
The large-scale production test of embodiment 4:PEDV inactivated vaccine
Test strain:, being obtained from Xibei Univ. of Agricultural & Forest Science & Technology by SX-YL plants of PEDV, which advises from Yangling Shaanxi
Modelling farm.
Test cell: Vero cell strain, the present of Xibei Univ. of Agricultural & Forest Science & Technology animal medicine institute veterinary vaccination laboratory.
Test method:
(1) recovery of Vero cell strain:
(1) the Vero cell being removed from liquid nitrogen quickly is put into 37 DEG C of water-baths, gently shaking makes its quick-thawing；
(2) 300 rpm are centrifuged 10 min；
(3) supernatant is abandoned, the cell culture fluid (containing 5% FBS DMEM) of 37 DEG C of pre-temperatures is added, gently dispels Vero cell；
(4) cell suspension after mixing is added to sterile T25 bottles containing 5m L5% FBS DMEM cell culture fluid
In, it is put in the suitable cell incubator of condition and cultivates；
(5) it after passage twice, is placed in culture to its cell in incubator and grows up to single layer, using the training of the embodiment of the present invention 1
After supporting base flushing 2 times, culture is continued to cell using the culture medium replacement culture in glassware liquid of the embodiment of the present invention 1 after cell is adherent
Grow up to fine and close single layer, then digest, cell suspension is made, by 4 T125 square vases 3/4 1 L this hair of cell suspension injection
Sufficiently shake up in the medium bottle of bright embodiment 1, finally pour into 1 L cell suspension in 10L rolling bottle, be stoppered bottle stopper be put into turn
Bottle machine is cultivated.
(2) culture of Vero cell in the bioreactor
It weighs appropriate I type microcarrier of Cytodex (purchased from GE) to set in reactor tank, and 1 L acid-base buffer is added
(PBS), dissolved oxygen, pH value electrode are calibrated, prepares alkali bottle (7. 5% sodium bicarbonate solutions), tank body is after the installation is completed 121
Sterilizing in DEG C pressure cooker takes out after 30 mim and carries out sterile test and (500 mL culture mediums are added and carry out preculture, mixing speed
For 50 r/h, oxyty 50%, pH value be 7. 20, temperature is 37 DEG C, lose pollution condition after 10 h), be then discharged out
PBS in tank, then will digest after the cell suspension to get off mixes and be injected into the culture medium of embodiment 1 of preparation in rolling bottle, it utilizes
Pipeline is injected into reactor, and regulating gas (compressed air, O2, N2, CO2) is simultaneously changed to automatically, and alkali bottle is adjusted to automatically
Addition, microcarrier suspension culture can be carried out by regulating revolving speed, every the cell density of monitoring in 15 minutes.
(3) inoculation and culture of PEDV
When culture vero cell Proliferation to 60 cells/ball cell density in bioreactor, to bioreactor
It is middle that the PEDV SX-YL strain virus liquid being diluted using the culture medium of the embodiment of the present invention 1 is added, dilute the drop of restrovirus liquid
Degree is 105.5TCID50, the volume ratio of the cell culture in virus liquid and bioreactor after dilution is 1:50.Dilution is added
After virus liquid, regulates revolving speed and carry out Virus culture, cultivate 24-26 hours, harvest virus-culturing fluid.
(4) preparation of PEDV inactivated vaccine
By the virus-culturing fluid of harvest at -80 DEG C, three times, 6000 rpm are centrifuged 20 min to multigelation, collect supernatant,
As virus liquid；Virus liquid is added 37 DEG C of 0.2% formaldehyde inactivations and obtains PEDV vaccinogen liquid in 24 hours after 20 times of concentrations；It will system
PEDV vaccinogen liquid and 206 adjuvant of adjuvant Montanide ISA press the volume ratio of 1.5:1, in gnotobasis, stirring is mixed
It closes uniformly, obtains pig epidemic diarrhea inactivated vaccine.
(5) vaccine test method and result
5.1 characters examine inactivated vaccine appearance pinkiness emulsion state.
5.2 steriling test inactivated vaccines according to existing " Republic of China Veterinary Pharmacopoeia " version third portion's annex in 2010 into
Performing check, T.G, G.P pipe and G.A slant medium do not observe bacterium colony.
5.3 mycoplasmas examine inactivated vaccine according to " Republic of China Veterinary Pharmacopoeia " version third portion's annex in 2010 into
Performing check does not find that significant change occur in bottle and tubule culture color, and the liquid culture of transplanting is on solid medium
Without " fried egg " shape mycoplasma bacterium colony.
5.4 exogenous virus examine inactivated vaccine according to " Republic of China Veterinary Pharmacopoeia " version third portion annex in 2010
It tests, is passed without swine fever virus, bovine viral diarrhea virus, pig parvoviral, porcine pseudorabies virus, rotavirus, pig
The pollution such as metachromia marcy agent.Prove that seed culture of viruses is pure.
It is negative 3 age in days pig 24 that 5.5 safety verifications, which take pig epidemic diarrhea neutralizing antibody, antigen, is randomly divided into
4 groups, every group 6,10 part vaccines of intramuscular injection, clinical observation 14 days, equal 100% strong work had no adverse reaction.
The test of embodiment 5:PEDV attenuated vaccine large scale preparation
It tests strain: CV777 plants of PEDV, obtaining the strain of Shaanxi Nowe Li Hua Biotechnology Co., Ltd preservation.
Test cell: Vero cell strain, the present of Xibei Univ. of Agricultural & Forest Science & Technology animal medicine institute veterinary vaccination laboratory.
Test method:
(1) recovery of Vero cell strain:
(1) the Vero cell being removed from liquid nitrogen quickly is put into 37 DEG C of water-baths, gently shaking makes its quick-thawing；
(2) 300 rpm are centrifuged 10 min；
(3) supernatant is abandoned, the cell culture fluid (containing 5% FBS DMEM) of 37 DEG C of pre-temperatures is added, gently dispels Vero cell；
(4) cell suspension after mixing is added to sterile T25 bottles containing 5m L5% FBS DMEM cell culture fluid
In, it is put in the suitable cell incubator of condition and cultivates；
(5) it after passage twice, is placed in culture to its cell in incubator and grows up to single layer, using the training of the embodiment of the present invention 1
After supporting base flushing 2 times, culture is continued to cell using the culture medium replacement culture in glassware liquid of the embodiment of the present invention 1 after cell is adherent
Grow up to fine and close single layer, then digest, cell suspension is made, by 4 T125 square vases 3/4 1 L this hair of cell suspension injection
Sufficiently shake up in the medium bottle of bright embodiment 1, finally pour into 1 L cell suspension in 10L rolling bottle, be stoppered bottle stopper be put into turn
Bottle machine is cultivated.
(2) culture of Vero cell in the bioreactor
It weighs appropriate I type microcarrier of Cytodex (purchased from GE) to set in reactor tank, and 1 L acid-base buffer is added
(PBS), dissolved oxygen, pH value electrode are calibrated, prepares alkali bottle (7. 5% sodium bicarbonate solutions), tank body is after the installation is completed 121
Sterilizing in DEG C pressure cooker takes out after 30 mim and carries out sterile test and (500 mL culture mediums are added and carry out preculture, mixing speed
For 50 r/h, oxyty 50%, pH value be 7. 20, temperature is 37 DEG C, lose pollution condition after 10 h), be then discharged out
PBS in tank, then will digest after the cell suspension to get off mixes and be injected into the culture medium of embodiment 1 of preparation in rolling bottle, it utilizes
Pipeline is injected into reactor, and regulating gas (compressed air, O2, N2, CO2) is simultaneously changed to automatically, and alkali bottle is adjusted to automatically
Addition, microcarrier suspension culture can be carried out by regulating revolving speed, every the cell density of monitoring in 15 minutes.
(3) inoculation and culture of PEDV
When culture vero cell Proliferation to 60 cells/ball cell density in bioreactor, to bioreactor
It is middle that the PEDV CV777 strain virus liquid being diluted using the culture medium of the embodiment of the present invention 1 is added, dilute the drop of restrovirus liquid
Degree is 105.5TCID50, the volume ratio of the cell culture in virus liquid and bioreactor after dilution is 1:50.Dilution is added
It after virus liquid, regulates revolving speed and carries out Virus culture, cultivate 24-26 hours, harvest virus-culturing fluid, the virus liquid of harvest is used
0.45/1.0 the membrane filtration clarification of micron.
(4) preparation of PEDV attenuated vaccine
Filtered virus liquid is taken, 2%(W/W is added) mannitol, 3%(W/W) dextran, 2%(W/W) glutamic acid
Sodium, 1%(W/W) urea, 0.2%(W/W) R-gene, 0.2%(W/W) the protective agents ingredient such as bovine serum albumin(BSA), it is made
Semi-finished product are lyophilized, which does not contain serum.Packing is lyophilized into cillin bottle, and every cillin bottle dispenses 0.5ml, through following
Program is lyophilized: pre-freeze: -45 DEG C, 3h；Drying temperature: -45 DEG C~30 DEG C；Drying process: -45 DEG C are maintained, 0.01 MPa
Then 3h increases 2 DEG C per hour.
In use, being redissolved using sterilized water for injection.(6) vaccine test method and result
6.1 steriling test attenuated vaccines are tested according to existing " Republic of China Veterinary Pharmacopoeia " version in 2010, T.G,
G.P pipe and G.A slant medium do not observe bacterium colony.
6.2 mycoplasmas examine attenuated vaccine to test according to " Republic of China Veterinary Pharmacopoeia " version in 2010, do not send out
There is significant change in existing bottle and tubule culture color, and the liquid culture of transplanting is on solid medium without " fried egg " shape branch
Bovis colony.
6.3 exogenous virus examine attenuated vaccine to test according to " Republic of China Veterinary Pharmacopoeia " version in 2010,
Without swine fever virus, bovine viral diarrhea virus, pig parvoviral, porcine pseudorabies virus, rotavirus, transmissible gastroenteritis of swine disease
The pollution such as poison.Prove that seed culture of viruses is pure.
It is negative 3 age in days pig 24 that 6.4 safety verifications, which take pig epidemic diarrhea neutralizing antibody, antigen, is randomly divided into
4 groups, every group 6,10 part vaccines of intramuscular injection, clinical observation 14 days, equal 100% strong work had no adverse reaction.
Embodiment 7: the comparison of different culture medium culture vero cell production PEDV CV777 virus
It tests strain: CV777 plants of PEDV, obtaining the strain of Shaanxi Nowe Li Hua Biotechnology Co., Ltd preservation.
Test cell: Vero cell strain, the present of Xibei Univ. of Agricultural & Forest Science & Technology animal medicine institute veterinary vaccination laboratory.
Test method: 96 orifice plates use 1-2 of the embodiment of the present invention, 10% newborn bovine serum+DMEM, check experiment example 1,
The culture medium culture vero cell of check experiment example 2 and check experiment example 3, every 50 μ LPEDV CV777 virus of hole inoculation, sealing
Culture plate is placed in 37 DEG C, cultivates in 5% carbon dioxide incubator afterwards, the virus titer in 12 hours measurement cell supernatants.
Comparative experimental example is set:
Comparative experimental example 1: referring to the comparative experimental example 1 in embodiment 3.
A kind of comparative experimental example 2: serum free medium, which is characterized in that the serum free medium by basal medium,
Bovine serum albumin(BSA), cortisol, insulin, transferrins, glutathione, trypsase, taurine and sodium selenite composition,
The weight ratio of middle taurine and sodium selenite is 1:1.
The basal medium IMDM(Giboc)；
The content of the bovine serum albumin(BSA) is 10mg/mL.
The content of the cortisol is 20 μ g/mL.
The content of the insulin is 20 μ g/mL.
The content of the transferrins is 15 μ g/mL.
The content of the glutathione is 3mM.
The content of the trypsase is 4 μ g/mL.
The content of the taurine is 10 μ g/mL.
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium is: step 1 weighs basal medium dry powder, ox blood by weight
Pure albumen, cortisol, insulin, transferrins, glutathione, trypsase, taurine and sodium selenite；Step 2, will
After the weighed above material mixing, add ultrapure water to 1000mL, stirring and dissolving adjusts pH value to 7.0-7.2, then uses 0.22
μm membrane filtration degerming, 4 DEG C of preservations.
A kind of comparative experimental example 3: serum free medium, which is characterized in that the serum free medium by basal medium,
Bovine serum albumin(BSA), cortisol, insulin, transferrins, trypsase, taurine and sodium selenite form, wherein taurine
Weight ratio with sodium selenite is 2:1.
The basal medium IMDM(Giboc)；
The content of the bovine serum albumin(BSA) is 10mg/mL.
The content of the cortisol is 20 μ g/mL.
The content of the insulin is 20 μ g/mL.
The content of the transferrins is 15 μ g/mL.
The content of the trypsase is 4 μ g/mL.
The content of the taurine is 20 μ g/mL.
The content of the sodium selenite is 10 μ g/mL.
The production method of the serum free medium is: step 1 weighs basal medium dry powder, ox blood by weight
Pure albumen, cortisol, insulin, transferrins, trypsase, taurine and sodium selenite；Step 2, more than weighed
After material mixing, add ultrapure water to 1000mL, stirring and dissolving adjusts pH value to 7.0-7.2, then uses 0.22 μm of membrane filtration
Degerming, 4 DEG C of preservations.
Test result: the following table 1 is participated in, as shown in Table 1, PEDV CV777 virus inoculation is in different culture mediums
State, in inoculation 12-48 hours, the virus titer highest for the culture medium being prepared with the embodiment of the present invention 1 and 2 was 6.5-
7.2, the virus titer of the embodiment of the present invention 1 and 2 is above 10% newborn bovine serum+DMEM, check experiment example 1, check experiment example
2 and check experiment example 3 culture medium.
Virus titer of the 1 PEDV CV777 virus inoculation of table after vero cell in different culture medium culture solution supernatant
(log2)
By the result of the above table 1 it is found that the embodiment of the present invention 1 and the culture medium of embodiment 2 have the proliferation of PEDV
There is preferable cultivation effect, adds DMEM culture medium compared to existing common calf serum, can more promote the proliferation of PEDV, increase
The virus titer grown is significantly raised, shows the increasing that culture medium of the invention can substitute traditional serum-containing media for PEDV
The preparation with vaccine is grown, immune problem caused by the use so as to avoid serum in vaccine production process；Itself and the present invention
The control experiment group of setting is compared, further demonstrate glutathione addition and taurine and sodium selenite ratio for
The importance of PEDV cell Proliferation is not added with glutathione in comparative experimental example 1, and the ratio of taurine and sodium selenite is also deposited
In difference, it is higher than the present invention, then its virus multiplication effect difference more of the present invention；Taurine and sodium selenite in comparative experimental example 2
Ratio is 1:1, i.e., taurine then causes virus multiplication too late expected using deficiency, although it is proliferated comparatively fast in the 0-12h stage,
But rise in the titre in virus multiplication later period slower；Glutathione is not added in comparative experimental example 3, then virus multiplication is not as good as pre-
Phase, early stage proliferation is relatively slow, and later period proliferation also shows slightly insufficient.The above test results show that in culture medium of the invention, paddy
Ratio the having great importance for PEDV cell Proliferation of the addition of the sweet peptide of Guang and taurine and sodium selenite, the two exists
It is synergistic in virus multiplication culture, achieve unexpected culture effect.
It is any in spirit and/or range of the invention due to describing the present invention by the above preferred embodiment
Implement the present invention for replacement/or combination of the invention, will be apparent from for those skilled in the art, and
Among the present invention.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810691800.0A CN108815516B (en) | 2018-06-29 | 2018-06-29 | A method of PEDV inactivated vaccine is produced using serum free medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810691800.0A CN108815516B (en) | 2018-06-29 | 2018-06-29 | A method of PEDV inactivated vaccine is produced using serum free medium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108815516A CN108815516A (en) | 2018-11-16 |
| CN108815516B true CN108815516B (en) | 2019-03-15 |
Family
ID=64134863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810691800.0A Active CN108815516B (en) | 2018-06-29 | 2018-06-29 | A method of PEDV inactivated vaccine is produced using serum free medium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815516B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110841064B (en) * | 2019-11-07 | 2020-11-27 | 衡阳师范学院 | A kind of canine adenovirus type I inactivated vaccine and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100482786C (en) * | 2007-12-28 | 2009-04-29 | 天津百若克医药生物技术有限责任公司 | Human embryo kidney 293 cell amplifying protein-free medium |
| EA201490945A1 (en) * | 2011-11-11 | 2014-08-29 | ЭССЕНШЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | SET, CONTAINING REPLACER OF SERUM AND LABOR FACTORS |
| CA2879624C (en) * | 2012-07-24 | 2023-10-17 | Nissan Chemical Industries, Ltd. | Culture medium composition, and method for culturing cell or tissue using said composition |
| EP3083978A4 (en) * | 2013-12-20 | 2017-08-30 | Bio-Ess Laboratories, LLC | Media for cell culture |
| CN105832759B (en) * | 2015-01-17 | 2020-06-09 | 广州自远生物科技有限公司 | A pharmaceutical composition for preventing and/or treating diseases caused by coronavirus and/or rotavirus |
| CN105441378A (en) * | 2015-12-22 | 2016-03-30 | 肇庆大华农生物药品有限公司 | Serum-free medium used for culturing Vero cells, and preparation method thereof |
-
2018
- 2018-06-29 CN CN201810691800.0A patent/CN108815516B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108815516A (en) | 2018-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105311630B (en) | A kind of mammalian cell suspension culture prepares the method and application of vaccine | |
| CN107460156B (en) | Serum-free full-suspension MDCK cell strain and application thereof in production of influenza virus | |
| CN108220221A (en) | A kind of method of full suspension cell culture recombinant fowl influenza subtype virus | |
| CN108853489B (en) | A method of PEDV attenuated vaccine is produced using serum free medium | |
| CN109913404A (en) | The preparation method of infections chicken cloacal bursa virus live vaccine | |
| CN108721615A (en) | A kind of method and its vaccine preparing duck tembusu virus inactivated vaccine | |
| CN108815516B (en) | A method of PEDV inactivated vaccine is produced using serum free medium | |
| CN114276981B (en) | Vero-E6 suspension cell strain sVero-E6 suitable for porcine epidemic diarrhea virus and application thereof | |
| CN102127524A (en) | Method for proliferating avian influenza viruses in bioreactor with cell carrier | |
| CN103923885B (en) | Infections chicken cloacal bursa virus Vero cell adapted strain and application thereof | |
| CN103861097A (en) | Method for preparing porcine epizootic diarrhea inactivated vaccines and product thereof | |
| CN105838683A (en) | Method for proliferation of mink canine distemper virus by applying novel cell microcarrier | |
| CN108421037A (en) | A kind of porcine pseudorabies/porcine parvovirus bivalent inactivated vaccine and its culture preparation method that suspends | |
| CN102727877A (en) | Method for preparing highly pathogenic porcine reproductive and respiratory syndrome live vaccine (JXA1-R strain) by utilizing bioreactor and application thereof | |
| CN108841780B (en) | It is suitble to the serum free medium of large-scale production PEDV vaccine | |
| CN105816872A (en) | Preparation method of mink parvoviral enteritis inactivated vaccine and vaccine prepared by using same | |
| CN105288610A (en) | Production technology and product of inactivated vaccine for avian influenza | |
| CN108159412A (en) | It is a kind of to produce cell source newcastle disease, method of bird flu bivalent inactivated vaccine and products thereof | |
| CN103861096A (en) | Preparation method of live vaccine for treating porcine reproductive and respiratory syndrome with high pathogenicity and live vaccine product | |
| CN110747176B (en) | Culture method for improving virus titer of porcine epidemic diarrhea viruses | |
| CN106237324A (en) | A kind of method using full suspension technology to produce transmissible gastroenteritis of swine vaccine | |
| CN108866012A (en) | A kind of Porcine epidemic diarrhea virus suspension culture is continuous to receive malicious production method | |
| CN104740627B (en) | A kind of large-scale method for producing of pseudo- mad dog attenuated live vaccines for animals | |
| CN107198771A (en) | The method that microcarrier suspension culture cell produces pseudorabies gE gene delection viral vaccines | |
| CN110241090B (en) | Method for producing porcine pseudorabies virus antigen by full suspension cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |